<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587001</url>
  </required_header>
  <id_info>
    <org_study_id>22219201</org_study_id>
    <nct_id>NCT01587001</nct_id>
  </id_info>
  <brief_title>The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis</brief_title>
  <official_title>The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Thoracic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC),
      on inflammation and oxidative stress in sarcoidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcoidosis is a granulomatous lung disease predominantly affecting the lungs. Reactive
      oxidative species are produced secondary to oxidative stress and inflammation and can affect
      key cellular processes. The investigators have shown a role for oxidative stress in chronic
      beryllium disease (CBD), a granulomatous disease that resembles sarcoidosis, and have also
      shown that antioxidant therapy reduces inflammation in CBD. Oxidative stress also plays a
      role in sarcoidosis but the exact mechanism and potential effect of antioxidant therapy on
      sarcoidosis is unknown. The investigators propose conducting a pilot study investigating the
      effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in
      sarcoidosis. The investigators will measure and compare markers of inflammation and oxidative
      stress in the lungs of sarcoidosis patients before and after treatment with NAC. The results
      of this study will prepare the investigators for a larger study investigating the role of NAC
      as a therapy for sarcoidosis with changes in lung function and x-ray as our primary outcome.
      This will provide the investigators with a new non-toxic therapy for sarcoidosis that can be
      used on its own or to supplement other therapies minimizing their toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels</measure>
    <time_frame>8 weeks of anti-oxidant therapy</time_frame>
    <description>Baseline peripheral blood mononuclear cells and bronchoalveolar lavage (BAL) lymphocyte percentages and lipopolysaccharide (LPS) stimulated tumor necrosis factor-α levels (pg/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar Lavage (BAL) Cell Glutathione (GSH) Levels</measure>
    <time_frame>8 weeks of anti-oxidant therapy</time_frame>
    <description>We measured changes at baseline and at 8 weeks in BAL whole cell total GSH levels and cellular 8-OHdG before and after treatment with NAC/placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Oral N-acetyl-cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral NAC 900mg three times daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo three times daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-acetyl-cysteine</intervention_name>
    <description>900mg three times daily for 8 weeks</description>
    <arm_group_label>Oral N-acetyl-cysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo three times daily for 8 weeks.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven sarcoidosis.

          -  Pulmonary parenchymal involvement with a Scadding chest x-ray stage II, III or IV.

          -  Abnormal spirometry and/or DLCO (&lt; 80% of predicted).

          -  Consenting adults : Age 18 years and above

        Exclusion Criteria:

          -  Positive lung washing or biopsy cultures for fungi or mycobacterial disease;

          -  Presence of other co-morbid conditions that may affect the patient's outcome.

          -  Patient inability to undergo venipuncture and BAL procedures.

          -  Current use of tobacco (smoking or otherwise) in the past 6 months

          -  Treatment with immunosuppressive therapy within the past 6 months.

          -  On oral anti-oxidant supplements.

          -  Active peptic ulcer disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabeel Hamzeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2012</study_first_posted>
  <results_first_submitted>March 21, 2016</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2016</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jennifer Brandorff</investigator_full_name>
    <investigator_title>Manager, Clinical Research Services, Regulatory</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>anti-oxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral N-acetyl-cysteine</title>
          <description>N-acetyl-cysteine: 900mg three times daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo</title>
          <description>Placebo: Matching placebo three times daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient samples to complete testing</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral N-acetyl-cysteine</title>
          <description>oral NAC 900mg three times daily for 8 weeks
N-acetyl-cysteine: 900mg three times daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Matching Placebo</title>
          <description>Placebo: Matching placebo three times daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="9"/>
                    <measurement group_id="B2" value="52" spread="13"/>
                    <measurement group_id="B3" value="53" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels</title>
        <description>Baseline peripheral blood mononuclear cells and bronchoalveolar lavage (BAL) lymphocyte percentages and lipopolysaccharide (LPS) stimulated tumor necrosis factor-α levels (pg/ml)</description>
        <time_frame>8 weeks of anti-oxidant therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral N-acetyl-cysteine</title>
            <description>N-acetyl-cysteine: 900mg three times daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo: Matching placebo three times daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels</title>
          <description>Baseline peripheral blood mononuclear cells and bronchoalveolar lavage (BAL) lymphocyte percentages and lipopolysaccharide (LPS) stimulated tumor necrosis factor-α levels (pg/ml)</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean baseline BAL cell TNF-a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40767" spread="25684"/>
                    <measurement group_id="O2" value="39938" spread="12033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean follow-up BAL cell TNF-a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45176" spread="17910"/>
                    <measurement group_id="O2" value="25671" spread="12203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean baseline PBMC cell TNF-a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2775" spread="2292"/>
                    <measurement group_id="O2" value="637" spread="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean follow-up PBMC cell TNF-a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3387" spread="2481"/>
                    <measurement group_id="O2" value="969" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchoalveolar Lavage (BAL) Cell Glutathione (GSH) Levels</title>
        <description>We measured changes at baseline and at 8 weeks in BAL whole cell total GSH levels and cellular 8-OHdG before and after treatment with NAC/placebo.</description>
        <time_frame>8 weeks of anti-oxidant therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral N-acetyl-cysteine</title>
            <description>oral NAC 900mg three times daily for 8 weeks
N-acetyl-cysteine: 900mg three times daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Placebo: Matching placebo three times daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage (BAL) Cell Glutathione (GSH) Levels</title>
          <description>We measured changes at baseline and at 8 weeks in BAL whole cell total GSH levels and cellular 8-OHdG before and after treatment with NAC/placebo.</description>
          <units>nmol/mg protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="2.94"/>
                    <measurement group_id="O2" value="9.39" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 week visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="3.64"/>
                    <measurement group_id="O2" value="4.28" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral N-acetyl-cysteine</title>
          <description>N-acetyl-cysteine: 900mg three times daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo</title>
          <description>Placebo: Matching placebo three times daily for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nabeel Hamzeh</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>303-270-2613</phone>
      <email>hamzehn@njhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

